{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T22:59:17Z","timestamp":1752361157943},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,10]]},"DOI":"10.7759\/cureus.48595","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T08:49:29Z","timestamp":1699606169000},"source":"Crossref","is-referenced-by-count":3,"title":["Utilizing Clinical and Non-clinical Patient Factors in Predicting Cardiovascular Events in Patients on JAK Inhibitor Therapy: A Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Kehinde O","family":"Sunmboye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Billy","family":"Bui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Salim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2442","article-title":"An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study","volume":"340","author":"Collins GS","year":"2010","unstructured":"Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ. 2010, 340:c2442. 10.1136\/bmj.c2442","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.13-4-395","article-title":"Cardiovascular risk and inflammatory rheumatic diseases","volume":"13","author":"Alhusain A","year":"2013","unstructured":"Alhusain A, Bruce IN. Cardiovascular risk and inflammatory rheumatic diseases. Clin Med (Lond). 2013, 13:395-7. 10.7861\/clinmedicine.13-4-395","journal-title":"Clin Med (Lond)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with jak inhibitors: a meta\u2010analysis","volume":"73","author":"Yates M","year":"2021","unstructured":"Yates M, Mootoo A, Adas M, et al.. Venous thromboembolism risk with jak inhibitors: a meta\u2010analysis. Arthritis Rheumatol. 2021, 73:779-88. 10.1002\/art.41580","journal-title":"Arthritis Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13317-021-00153-5","article-title":"Effect of Janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solipuram V","year":"2021","unstructured":"Solipuram V, Mohan A, Patel R, Ni R. Effect of Janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Auto Immun Highlights. 2021, 12:8. 10.1186\/s13317-021-00153-5","journal-title":"Auto Immun Highlights"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1237234","article-title":"Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis","volume":"14","author":"Wei Q","year":"2023","unstructured":"Wei Q, Wang H, Zhao J, et al.. Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis. Front Pharmacol. 2023, 14:1237234. 10.3389\/fphar.2023.1237234","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.060042","article-title":"Socioeconomic deprivation: An important, largely unrecognized risk factor in primary prevention of cardiovascular disease","volume":"146","author":"Kimenai DM","year":"2022","unstructured":"Kimenai DM, Pirondini L, Gregson J, et al.. Socioeconomic deprivation: An important, largely unrecognized risk factor in primary prevention of cardiovascular disease. Circulation. 2022, 146:240-8. 10.1161\/CIRCULATIONAHA.122.060042","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009984","article-title":"Impact of socioeconomic deprivation on screening for cardiovascular disease risk in a primary prevention population: a cross-sectional study","volume":"6","author":"Lang SJ","year":"2016","unstructured":"Lang SJ, Abel GA, Mant J, Mullis R. Impact of socioeconomic deprivation on screening for cardiovascular disease risk in a primary prevention population: a cross-sectional study. BMJ Open. 2016, 6:e009984. 10.1136\/bmjopen-2015-009984","journal-title":"BMJ Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.07.022","article-title":"Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"Cavallari LH","year":"2018","unstructured":"Cavallari LH, Lee CR, Beitelshees AL, et al.. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018, 11:181-91. 10.1016\/j.jcin.2017.07.022","journal-title":"JACC Cardiovasc Interv"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005809","article-title":"The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study","volume":"4","author":"Hippisley-Cox J","year":"2014","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study. BMJ Open. 2014, 4:e005809. 10.1136\/bmjopen-2014-005809","journal-title":"BMJ Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd6020019","article-title":"Cardiovascular risks associated with gender and aging","volume":"6","author":"Rodgers JL","year":"2019","unstructured":"Rodgers JL, Jones J, Bolleddu SI, et al.. Cardiovascular risks associated with gender and aging. J Cardiovasc Dev Dis. 2019, 6:10.3390\/jcdd6020019","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"17","author":"Borren NZ","year":"2019","unstructured":"Borren NZ, Ananthakrishnan AN. Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019, 17:1736-1743.e4. 10.1016\/j.cgh.2018.12.032","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1669-x","article-title":"Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study","volume":"20","author":"Lee JL","year":"2018","unstructured":"Lee JL, Sinnathurai P, Buchbinder R, Hill C, Lassere M, March L. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study. Arthritis Res Ther. 2018, 20:171. 10.1186\/s13075-018-1669-x","journal-title":"Arthritis Res Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197390","article-title":"Clinical aspects of Janus kinase (jak) inhibitors in the cardiovascular system in patients with rheumatoid arthritis","volume":"21","author":"Kotyla PJ","year":"2020","unstructured":"Kotyla PJ, Islam MA, Engelmann M. Clinical aspects of Janus kinase (jak) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. Int J Mol Sci. 2020, 21:7390. 10.3390\/ijms21197390","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1077632","article-title":"Assessment of QRISK3 as a predictor of cardiovascular disease events in type 2 diabetes mellitus","volume":"13","author":"Mu X","year":"2022","unstructured":"Mu X, Wu A, Hu H, Zhou H, Yang M. Assessment of QRISK3 as a predictor of cardiovascular disease events in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022, 13:1077632. 10.3389\/fendo.2022.1077632","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-304474","article-title":"Ethnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort study (SABRE--Southall And Brent REvisited)","volume":"100","author":"Tillin T","year":"2014","unstructured":"Tillin T, Hughes AD, Whincup P, Mayet J, Sattar N, McKeigue PM, Chaturvedi N. Ethnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort study (SABRE--Southall And Brent REvisited). Heart. 2014, 100:60-7. 10.1136\/heartjnl-2013-304474","journal-title":"Heart"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(21)00088-X","article-title":"Effect of competing mortality risks on predictive performance of the QRISK3 cardiovascular risk prediction tool in older people and those with comorbidity: external validation population cohort study","volume":"2","author":"Livingstone S","year":"2021","unstructured":"Livingstone S, Morales DR, Donnan PT, Payne K, Thompson AJ, Youn JH, Guthrie B. Effect of competing mortality risks on predictive performance of the QRISK3 cardiovascular risk prediction tool in older people and those with comorbidity: external validation population cohort study. Lancet Healthy Longev. 2021, 2:e352-61. 10.1016\/S2666-7568(21)00088-X","journal-title":"Lancet Healthy Longev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-302168","article-title":"Methods for assessing cardiovascular disease risk in a UK black population","volume":"98","author":"Schofield P","year":"2012","unstructured":"Schofield P, Crichton N, Chen R. Methods for assessing cardiovascular disease risk in a UK black population. Heart. 2012, 98:1373-7. 10.1136\/heartjnl-2012-302168","journal-title":"Heart"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0178","article-title":"Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review","volume":"11","author":"Jegatheeswaran J","year":"2019","unstructured":"Jegatheeswaran J, Turk M, Pope JE. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. Immunotherapy. 2019, 11:737-54. 10.2217\/imt-2018-0178","journal-title":"Immunotherapy"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis","volume":"95","author":"Wang F","year":"2020","unstructured":"Wang F, Sun L, Wang S, et al.. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc. 2020, 95:1404-19. 10.1016\/j.mayocp.2020.01.039","journal-title":"Mayo Clin Proc"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard L","year":"2022","unstructured":"Hoisnard L, Lebrun-Vignes B, Maury S, et al.. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022, 12:7140. 10.1038\/s41598-022-10777-w","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/200682-utilizing-clinical-and-non-clinical-patient-factors-in-predicting-cardiovascular-events-in-patients-on-jak-inhibitor-therapy-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:36Z","timestamp":1707509436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/200682-utilizing-clinical-and-non-clinical-patient-factors-in-predicting-cardiovascular-events-in-patients-on-jak-inhibitor-therapy-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.48595","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,10]]}}}